Proteins IL-6 , Human
- Known as:
- Proteins Interleukin-6 , Human
- Catalog number:
- C009
- Product Quantity:
- 10μg
- Category:
- -
- Supplier:
- Novoprotein
- Gene target:
- Proteins IL-6 Human
Related genes to: Proteins IL-6 , Human
- Gene:
- CEBPB NIH gene
- Name:
- CCAAT enhancer binding protein beta
- Previous symbol:
- TCF5
- Synonyms:
- LAP, CRP2, NFIL6, IL6DBP, C/EBP-beta
- Chromosome:
- 20q13.13
- Locus Type:
- gene with protein product
- Date approved:
- 1991-02-27
- Date modifiied:
- 2018-02-23
- Gene:
- CEBPD NIH gene
- Name:
- CCAAT enhancer binding protein delta
- Previous symbol:
- -
- Synonyms:
- CRP3, CELF, C/EBP-delta, NF-IL6-beta
- Chromosome:
- 8q11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-24
- Date modifiied:
- 2018-02-23
- Gene:
- ENTPD6 NIH gene
- Name:
- ectonucleoside triphosphate diphosphohydrolase 6
- Previous symbol:
- CD39L2, IL6ST2
- Synonyms:
- NTPDase-6, dJ738P15.3
- Chromosome:
- 20p11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-20
- Date modifiied:
- 2019-02-28
- Gene:
- IL6 NIH gene
- Name:
- interleukin 6
- Previous symbol:
- IFNB2
- Synonyms:
- IL-6, BSF2, HGF, HSF
- Chromosome:
- 7p15.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2017-07-12
- Gene:
- IL6RP1 NIH gene
- Name:
- interleukin 6 receptor pseudogene 1
- Previous symbol:
- IL6RL1
- Synonyms:
- -
- Chromosome:
- 9q22.2
- Locus Type:
- pseudogene
- Date approved:
- 1991-08-18
- Date modifiied:
- 2014-11-19
Related products to: Proteins IL-6 , Human
Related articles to: Proteins IL-6 , Human
- Sepsis-associated kidney injury (S-AKI) is a severe complication of sepsis, yet effective targeted therapies remain limited. We investigated the renoprotective effects of Tubuloside A (TA) and its mechanisms. S-AKI was induced in mice by cecal ligation and puncture, whereas an in vitro model was established using HK-2 cells exposed to lipopolysaccharide. Network pharmacology and molecular docking were used to explore potentially relevant targets and signaling pathways, and the involvement of autophagy-related processes was further examined using 3-methyladenine (3-MA). TA attenuated renal histopathological injury, reduced serum blood urea nitrogen and creatinine levels, and decreased the expression of the kidney injury markers KIM-1 and NGAL. TA also suppressed IL-1β, IL-6, and TNF-α expression while increasing IL-10 expression. TA also reduced ROS and MDA levels and increased CAT, GSH, and T-AOC activities, indicating antioxidant capacity. TA reduced Bax, cleaved caspase-3, and cleaved caspase-9 expression, increased Bcl-2 expression, and decreased the proportion of Annexin V-FITC/PI-positive cells. TA decreased the p-mTOR/mTOR ratio and p62 expression while increasing the LC3B-II/LC3B-I ratio, indicating modulation of mTOR-associated autophagy-related markers. TA also inhibited NF-κB activation, as evidenced by reduced p-p65 and p-IκBα levels, restored IκBα expression, and decreased nuclear p-p65 accumulation. CETSA further showed that TA altered the thermal stability profile of p65, providing experimental support for potential cellular target engagement of p65 by TA. Notably, 3-MA partially reversed these effects. Collectively, TA protects against S-AKI by alleviating inflammation, oxidative stress, and apoptosis, possibly through modulation of mTOR-associated autophagy-related processes and NF-κB signaling. - Source: PubMed
Publication date: 2026/10/02
Ni QingyanWang MingxuePu XiaoyingLiu ShujuanXu XiaolongFu Mian - Aspiration pneumonia (AP) is a common and serious respiratory disease among the elderly, with current treatments limited primarily to antibiotics and supportive care, highlighting a need for targeted therapies. Yeast β-1,3/1,6-glucan (YBG), a natural polysaccharide derived from yeast cell walls, holds immunomodulatory and antioxidant properties. However, its mechanism in AP remains unclear. - Source: PubMed
Publication date: 2026/10/02
Li QinLi ChongjinYang LiWang YuNi YuxinLi QianJia QingdongYuan MinjieHu Caibao - Polycyclic aromatic hydrocarbons (PAHs), including benzo[g,h,i]perylene (BGP) and benzo[b]fluoranthene (BBF), are ubiquitous airborne pollutants with significant toxicological relevance. Inhalation represents the primary exposure route, with the respiratory epithelium and alveolar macrophages serving as key targets for adverse effects. Despite their prevalence, mechanistic data on BGP and BBF, particularly in respiratory cell models, remain limited. Here, we evaluated the cytotoxic, genotoxic, and cytokine-associated effects of BGP and BBF in a co-culture of human alveolar epithelial (A549) and macrophage-like differentiated (dTHP-1) cells maintained at a pseudo-air-liquid interface (pseudo-ALI). No detectable genotoxic effects were observed following 24h exposure to non‑cytotoxic concentrations of BGP (≤ 18.1µM) and BBF (≤ 39.6µM), as evidenced by the absence of DNA double‑strand breaks, phospho‑histone H3 activation, and micronucleus formation. In contrast, both compounds modulated several inflammatory cytokine-associated endpoints, with BGP producing a stronger effect than BBF. BGP significantly increased IL-8 secretion and the proportion of cells expressing TNF-α, IL-6, and IL-1β, while BBF moderately elevated the proportion of cells expressing TNF-α, IL-6, and IFN-γ. Targeted qPCR analysis detected changes in selected cytokine-associated genes. These findings indicate that BGP, and to a lesser extent BBF, modulated selected inflammatory cytokines without detectable DNA damage under the tested conditions. Limited metabolic activation may have contributed to the negative genotoxicity findings; however, metabolic activity and PAH metabolite formation were not assessed in this co-culture. The results highlight inflammatory cytokine-associated effects, particularly following BGP exposure, and demonstrate the value of the A549/dTHP-1 co-culture for investigating early cellular responses to PAHs. - Source: PubMed
Publication date: 2026/10/02
Novak MatjažŠtampar MartinaŠtern AljaBurgum Michael JConway Gillian EGajski GoranDoak Shareen HŽegura Bojana - Anthocleista nobilis, a West African medicinal plant, has traditionally been used for rheumatism, arthritis, pain, inflammatory conditions, and metabolic disorders. However, direct ethnobotanical evidence for its traditional use specifically against gout is limited. The present study therefore pharmacologically explored the potential of A. nobilis ethanolic extract (ANEE) in gout-related experimental models. - Source: PubMed
Publication date: 2026/10/02
Huang JianglingRuan YuhengTang GupingKeita SoundiataTouré AnsoumaneWang DaijunWang Min - Cyclophosphamide (CP) is a widely used chemotherapeutic agent; however, its clinical utility is limited by severe adverse effects, including nephrotoxicity. Therefore, the present study investigated the nephroprotective potential of rotundic acid (RA) against CP-induced renal toxicity in mice. RA is a natural pentacyclic triterpene reported to possess anticancer, antioxidant, anti-inflammatory, and antidiabetic activity. A molecular docking analysis has demonstrated that RA exhibits a substantial affinity for the pocket domain of TGF-β1, thereby indicating the nephroprotective potential of RA. Animal were randomly assigned to 7 groups. Control; CP 200; RA 10 + CP 200; RA 20 + CP 200; RA 40 + CP 200; NER 400 + CP 200 and RA 40 per se. RA was given orally for 14 days, and CP 200 mg/kg, i.p., once on the 7th day. On the 15th day animals were sacrificed, and kidney were isolated for study. CP 200 group significant nephrotoxicity in term of oxidative stress, inflammation, fibrosis and apoptosis as demonstrated by decreased levels of SOD, GSH, catalase, IL-10 and increased TBARS, nitrite, TNF-α, IL-6, IL-1β, urea, uric acid, creatinine, and BUN. NF-κB, cleaved caspase-3 and TGF-β1 expression was also increased and histopathological tissue architecture change. RA 20, 40 mg/kg effectively normalized these damages and confirmed nephroprotective effect. The findings indicate that RA may effectively mitigate CP-induced nephrotoxicity and could be considered a potential adjuvant to CP in cancer therapy. However, further studies using appropriate cancer models are essential to confirm and validate its therapeutic potential. - Source: PubMed
Publication date: 2026/09/29
Moonis MohammadVohora DivyaHaque Syed Ehtaishamul